NDAORALCAPSULEPriority Review
Approved
Apr 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
5/8 — Partial
Priority Review
VIVJOA (oteseconazole) by Mycovia Pharmaceuticals is breast cancer resistance protein inhibitors [moa]. First approved in 2022.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIVJOA (oteseconazole) is an oral azole antifungal that works by inhibiting breast cancer resistance protein, enabling improved fungal penetration and efficacy. It was approved in April 2022 for treatment of serious fungal infections in immunocompromised patients. The drug represents a novel mechanism within the azole class, offering potential advantages in bioavailability and tissue penetration.
$0.222MPart D
Peak9.7 years to LOEEarly adoption with modest Part D claims signals niche specialty positioning; commercial teams focused on targeted hospital and infectious disease specialist channels.
Mechanism of Action
Breast Cancer Resistance Protein Inhibitors
Pharmacologic Class:
Azole Antifungal
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections
Started Mar 2019
219 enrolled
Recurrent Vulvovaginal Candidiasis
A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Started Aug 2018
425 enrolled
Recurrent Vulvovaginal Candidiasis
A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Started Aug 2018
438 enrolled
Recurrent Vulvovaginal Candidiasis
Career Relevance
Working on VIVJOA offers specialized expertise in rare/serious fungal infection treatment and hospital-based specialty sales, with high technical involvement in infectious disease channels. The niche market and emerging commercial phase provide early-stage growth opportunities and close relationships with key opinion leaders in hospital epidemiology and critical care.
Worked on VIVJOA at Mycovia Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.